05 July 2019
Visiongain has launched a new pharma report Global Influenza Vaccines Market Report : Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other.
Growth is mainly driven by the ageing population and the increasing prevalence of health problems associated with age. This will drive the demand from both the developing and the developed world for influenza vaccines. The emerging markets will benefit from improved healthcare systems and in turn they will add to the demand of the influenza vaccines owing to their high birth rates. Furthermore, research and development will lead to continuous innovation within the vaccines industry. Advancements will be made in the delivery and target technology used in the influenza vaccines.
The lead analyst of the report commented "The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market. There is an increasing focus to identify the research gaps and unmet needs of the influenza vaccines market. This includes vaccine technology that provides wider coverage and easier access and administration of the influenza vaccines. This breeds a strong platform for both start-ups and larger pharmaceutical companies to create newer influenza vaccine technology that is not already on the market. This prevents stagnation within the market and will help drive the growth of the influenza vaccines market."
Leading companies featured in the report include Sanofi Pasteur, Seqirus, GlaxoSmithKline (GSK), AstraZeneca, Abbott Laboratories, Sinovac Biotech and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.
18 January 2021
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.
12 January 2021
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.
11 January 2021
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.